Moxifloxacin + KetorolacThird Party Manufacturing in India

Moxifloxacin + Ketorolac works by combining rapid bactericidal defense with rapid cyclooxygenase inhibition. Moxifloxacin stops bacterial proliferation by inhibiting topoisomerase IV and DNA gyrase, causing irreversible chromosomal breaks. Ketorolac tromethamine works as a competitive inhibitor of cyclooxygenase-1 and cyclooxygenase-2 enzymes, resulting in a sudden halt to prostaglandin synthesis in the anterior chamber. Unlike traditional single-agent anti-infectives, this combination addresses the mechanical discomfort and redness of an eye injury while maintaining a clear sterile pathway. It is highly effective and well-tolerated.

Therapeutic Uses

• Acute Bacterial Conjunctivitis: Relieves intense localized pain and itching while eradicating underlying pathogenic bacteria.
• Post-Surgical Analgesia: Mitigates pain and mitigates infection following corneal scrapings or foreign body removals.
• Seasonal Conjunctivitis Management: Prevents secondary bacterial colonization in patients with severe scratching behaviors.

Why Manufacturers Choose Moxifloxacin + Ketorolac

This combination offers clear advantages due to its ability to provide immediate symptomatic relief from pain, making it highly preferred by retail customers and hospital chains. Utilizing Moxifloxacin + Ketorolac third party manufacturing in India gives distribution networks a high-margin product suitable for nationwide distribution. Our partner facilities are WHO-GMP certified, which guarantees accurate preservative levels and sterile processing for this CAS 135738-90-2 combination.